We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals
IONS

396 hedge funds and large institutions have $8.14B invested in Ionis Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 167 increasing their positions, 95 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more repeat investments, than reductions

Existing positions increased: 167 | Existing positions reduced: 95

20% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 56

5.36% more ownership

Funds ownership: 84.87% → 90.24% (+5.4%)

1% more funds holding

Funds holding: 392 → 396 (+4)

15% less capital invested

Capital invested by funds: $9.53B → $8.14B (-$1.39B)

32% less call options, than puts

Call options by funds: $81.3M | Put options by funds: $119M

40% less funds holding in top 10

Funds holding in top 10: 10 → 6 (-4)

Holders
396
Holders Change
+4
Holders Change %
+1.02%
% of All Funds
8.6%
Holding in Top 10
6
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-40%
% of All Funds
0.13%
New
67
Increased
167
Reduced
95
Closed
56
Calls
$81.3M
Puts
$119M
Net Calls
-$38M
Net Calls Change
+$75.6M

Top Buyers

1
BG
Bellevue Group
Switzerland
+$541M
2
Invesco
Invesco
Georgia
+$155M
3
Renaissance Technologies
Renaissance Technologies
New York
+$124M
4
BlackRock
BlackRock
New York
+$83.5M
5
State Street
State Street
Massachusetts
+$73M

Top Sellers

1
First Trust Advisors
First Trust Advisors
Illinois
-$63.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$34.1M
3
PP
PDT Partners
New York
-$27.7M
4
FLAM
First Light Asset Management
Minnesota
-$20.1M
5
SI
Scout Investments
Missouri
-$15.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
BRWA
251
B. Riley Wealth Advisors
Florida
$312K +$342K +4,843 New
BAS
252
Brown Advisory Securities
Maryland
$308K -$21.2K -300 -6%
Mercer Global Advisors
253
Mercer Global Advisors
Colorado
$308K +$124K +1,749 +58%
SP
254
Symmetry Partners
Connecticut
$303K +$282K +3,983 +542%
Rockefeller Capital Management
255
Rockefeller Capital Management
New York
$292K -$214K -3,034 -40%
CIBC Asset Management
256
CIBC Asset Management
Ontario, Canada
$289K – – –
RJT
257
Raymond James Trust
Florida
$287K -$1.63K -23 -0.5%
FAAS
258
First Allied Advisory Services
California
$287K +$6.71K +95 +2%
AC
259
Allstate Corporation
Illinois
$286K +$314K +4,443 New
RFC
260
Regions Financial Corp
Alabama
$284K +$3.46K +49 +1%
Mirae Asset Global Investments
261
Mirae Asset Global Investments
South Korea
$282K +$9.12K +129 +3%
WAM
262
World Asset Management
Michigan
$275K +$2.76K +39 +0.9%
SLAM
263
Swiss Life Asset Management
$271K +$298K +4,211 New
MML Investors Services
264
MML Investors Services
Massachusetts
$266K +$73.2K +1,036 +33%
QT
265
Quantamental Technologies
New York
$262K +$288K +4,074 New
WFMPM
266
Woodley Farra Manion Portfolio Management
Indiana
$261K -$6.22K -88 -2%
IA
267
IFG Advisory
Georgia
$261K +$4.1K +58 +1%
QI
268
QS Investors
New York
$258K – – –
BAM
269
Berkshire Asset Management
Pennsylvania
$248K +$62.1K +878 +29%
CC
270
Cannell & Co
New York
$247K – – –
FT
271
Fiduciary Trust
Massachusetts
$246K -$24.7K -350 -8%
FCCM
272
First City Capital Management
Georgia
$246K – – –
IWP
273
Icon Wealth Partners
Texas
$244K +$66.8K +945 +33%
BNP Paribas Asset Management
274
BNP Paribas Asset Management
France
$231K +$254K +3,593 New
GIM
275
Granahan Investment Management
Massachusetts
$228K +$250K +3,541 New
9 10
11
12 13

IONS Hedge Fund Activity: Q2 2019 in Review

396 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2019, worth a combined $8.14B — down 15% from $9.53B a quarter earlier.

Buyers outnumbered sellers: 67 funds opened new IONS positions and 56 closed out — a net gain of 11 holders — while 167 added to existing stakes and 95 trimmed.

The largest buyer was Bellevue Group, adding an estimated $541M. The largest seller was First Trust Advisors, cutting an estimated $63.9M.

  • 396 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2019, up from 392 in Q1 2019.
  • Funds reported $8.14B of Ionis Pharmaceuticals stock for Q2 2019, down 15% quarter-over-quarter.
  • 67 funds opened new Ionis Pharmaceuticals positions in Q2 2019 and 56 closed out, a net change of +11 holders.
  • The largest Ionis Pharmaceuticals buyer in Q2 2019 was Bellevue Group, an estimated $541M added.
  • The largest Ionis Pharmaceuticals seller in Q2 2019 was First Trust Advisors, an estimated $63.9M sold.

Based on aggregated 13F filings for Q2 2019.